ReviewMolecular biomedicine2026
Epigenetic regulatory networks in the pathogenesis and treatment of osteoporosis subtypes.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Osteoporosis is a systemic skeletal disorder characterized by reduced bone mineral density and heightened bone fragility, encompassing primary (senile and postmenopausal) and secondary (glucocorticoid-induced and diabetic) subtypes. Maintaining skeletal health relies on the dynamic balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Among the multitude of factors orchestrating this bone remodeling process, epigenetics, which regulates gene expression via reversible chemical modifications without altering the primary DNA sequence, plays an essential role in maintaining bone homeostasis. While previous research has identified numerous epigenetic factors in bone metabolism, a comprehensive synthesis of their specific contributions to different osteoporosis subtypes and the corresponding therapeutic strategies remains lacking. This review outlines the major epigenetic mechanisms involved in bone metabolism, including DNA methylation, histone modifications, RNA modifications, and non-coding RNAs. Subsequently, we comprehensively elucidate how the dysregulation of these epigenetic landscapes drives the pathogenesis of distinct osteoporosis subtypes, emphasizing their roles in disrupting the osteoblast-osteoclast axis. Furthermore, we review emerging epigenetic-based therapeutics across distinct osteoporosis subtypes, ranging from systemic pharmacological inhibitors, such as DNA methyltransferase and histone demethylase inhibitors, to advanced delivery platforms targeting the skeletal microenvironment, such as engineered extracellular vesicles and functionalized nanocarriers. By integrating molecular mechanistic insights with these diverse therapeutic strategies, this review establishes a comprehensive framework for understanding the epigenetic heterogeneity in the pathogenesis and therapeutics of osteoporosis. Ultimately, it provides essential directions for future investigations, offering innovative epigenetic strategies to tackle various osteoporosis subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.